www.bostonglobe.com

www.bostonglobe.com
Share

www.bostonglobe.com

 •  February 13

The Food and Drug Administration on Monday approved a treatment for cystic fibrosis that combines Vertex Pharmaceuticals Inc’s Kalydeco with another medicine, Vertex said, marking the company’s third product for the life-shortening lung disorder, according to Reuters. The list price of SYMDEKO is $292,000 per year, but that is not the price...

www.bostonglobe.com

 •  January 31

mid rising tension between drug makers and compound pharmacies, the Food and Drug Administration has issued new policies that seek to bolster manufacturing standards for compounded medicines and, in the process, may serve to establish competitive boundaries between these rival sets of companies.A key piece of the effort focuses on a contentious...

www.bostonglobe.com

 •  December 21, 2017

Shares of Biogen Inc. dropped more than 3 percent Thursday after the Cambridge biotech reported that an experimental Alzheimer’s drug it’s co-developing with a Japanese company showed disappointing results in a mid-stage clinical trial. But the setback affects only one of a half dozen compounds Biogen is developing to target Alzheimer’s disease,...

www.bostonglobe.com

 •  September 24, 2017

Attorney General Maura Healey, along with attorneys general from 38 other states, is seeking information from five opioid manufacturers and three distributors as they expand an investigation into the origins of the addiction crisis that has claimed thousands of lives. At an announcement Tuesday in Boston, Healey said the attorneys general are...

www.bostonglobe.com

 •  August 5, 2017

nly three types of drug-resistant bacteria make the Center for Disease Control and Prevention’s list of “urgent” threats. One of them is gonorrhea. That particular sexually transmitted infection is the target of a new drug being developed by Entasis, an antibiotics-focused spin-off from pharma giant AstraZeneca. But they’re getting help: their...

www.bostonglobe.com

 •  July 27, 2017

Repeated scandals helped create the Food and Drug Administration we know today: a thriving agency that effectively protects consumers and patients from unsafe food and drugs. However, Congress is overdue in passing legislation necessary to keep the FDA running, with one senator threatening further delay to force adoption of a policy that limits the...

www.bostonglobe.com

 •  July 10, 2017

An experimental hemophilia drug developed by Alnylam Pharmaceuticals continues to stanch bleeding in patients followed for almost one year in an ongoing, mid-stage clinical trial, the company reported Monday. The promising results could intensify an already heated competition to develop novel treatments for the inherited bleeding disorder. The...

www.bostonglobe.com

 •  June 9, 2017

What is it? A pigeon as a drug mule Innovator: Iraqi drug smugglers What were they thinking? Kuwait likes to party — or at least some people there do. But scoring party drugs can be a challenge. Enter the party fowl. Kuwaiti newspaper Al Rai recently reported that drug smugglers in neighboring Iraq recently affixed a tiny backpack to a pigeon and...

www.bostonglobe.com

 •  May 9, 2017

French pharmaceutical giant Sanofi SA, which became a major player in Boston area biotech when it bought Genzyme Corp. in 2011, unveiled a drug pricing policy Tuesday that includes limiting annual US increases to a federal government health spending gauge. Sanofi, which sells more than 70 medicines and vaccines in the United States, is the latest...

www.bostonglobe.com

 •  April 25, 2017

Biogen Inc. released data Monday from a late-stage clinical trial showing its recently approved treatment for spinal muscular atrophy significantly improved motor function in older children with later-onset types of the neuromuscular disease. The findings, to be presented at the American Academy of Neurology annual meeting in Boston, are likely to...